Waters stock holds above $410 as guidance and valuation draw attention

Waters Corp (US9418481035) stock has been trading above $410 per share in recent sessions, as of mid-August 2026, while management reiterates Q3 and full-year 2026 EPS guidance for the current year.

Guidance and earnings expectations

Per a recent earnings and guidance overview dated August 17, 2026, Waters has set its Q3 2026 EPS guidance in a range of $3.95 to $4.05, giving investors a concrete view on expected near-term profitability.

The same overview indicates that Waters management expects full-year 2026 EPS in a range of $14.45 to $14.65, which frames the current year’s earnings power and underpins analyst models for the company.

Sell-side forecasts compiled in that report point to 2026 EPS of 14.57, placing the consensus estimate close to the midpoint of management’s guidance range and suggesting a relatively tight alignment between internal expectations and external models.

Analyst sentiment summarized in the August 17, 2026 review shows a moderate buy stance on Waters shares, with a mix of strong buy, buy, and hold ratings that reflects confidence in the earnings trajectory but also recognition of valuation constraints.

Alongside earnings expectations, the guidance commentary highlights that Waters designs, manufactures, and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems, supporting recurring demand from pharmaceutical, life sciences, and industrial customers.

Valuation and sector context

A separate valuation-focused analysis released August 17, 2026 discusses Waters stock through the lens of price-to-sales multiples, indicating that the shares currently trade on a P/S ratio of 8.7 times based on recent revenue figures.

That same discussion compares Waters’ P/S multiple with a life sciences industry average of 4.1 times and a peer group average of 5.3 times, quantifying how far Waters’ valuation stands above broader sector benchmarks.

The spread between Waters’ 8.7 times P/S multiple and the 5.3 times peer average amounts to 3.4 turns of sales, which is a meaningful premium investors are paying for the company’s measurement and analytical technologies platform.

By contrast to peers and the wider life sciences space, this premium suggests that investors are assigning a high value to Waters’ operating margins, cash generation, and exposure to regulated end markets, even as they weigh the risks of multiple compression if growth slows.

The valuation commentary argues that part of the justification for Waters’ premium comes from the company’s steady demand in chromatography and mass spectrometry instruments, where replacement cycles and consumables help smooth revenue over time.

Business portfolio and key products

Waters’ core business revolves around advanced analytical instruments and related software that help customers separate, identify, and quantify chemical compounds in complex samples.

In liquid chromatography, Waters provides high performance liquid chromatography systems, columns, and consumables that enable precise separation of molecules for pharmaceutical development and quality control applications.

In mass spectrometry, Waters’ platforms pair with chromatography systems to deliver detailed mass-to-charge measurements, giving researchers and quality laboratories powerful tools to detect trace impurities or confirm molecular structures.

The company also supports separation science more broadly through systems that are tailored for specific workflows, such as bioanalysis, food safety testing, environmental monitoring, and clinical diagnostics.

Sample preparation tools and detection systems complement these instruments, as customers require robust upstream steps and reliable signal acquisition to ensure accurate and repeatable results.

Waters’ software solutions integrate instrument control, data acquisition, and analysis into unified workflows that fit regulatory requirements such as good laboratory practice and good manufacturing practice, adding to the stickiness of the installed base.

Stock level and investor view

Waters stock recently opened trading at $411.88 per share on a mid-August 2026 session, providing a reference level that investors can compare with the company’s earnings guidance and valuation metrics.

That price level sits against the backdrop of the 8.7 times price-to-sales multiple discussed in the August 17, 2026 valuation note, underscoring that Waters shares remain at a premium compared with the 4.1 times life sciences industry average and the 5.3 times peer group average.

For investors, the key question is whether Waters’ Q3 2026 EPS guidance of $3.95 to $4.05 and full-year 2026 EPS guidance of $14.45 to $14.65, together with the consensus forecast of 14.57, are sufficient to sustain the current premium and support long-term returns.

Liquid chromatography and mass spectrometry focus

A representative example of Waters’ offering is its liquid chromatography and mass spectrometry platforms, which sit at the center of the company’s measurement technologies.

In many pharmaceutical and biopharmaceutical workflows, Waters’ systems are used to profile active pharmaceutical ingredients, monitor impurities at low concentrations, and verify batch consistency before products are released.

Food safety laboratories rely on these platforms to detect contaminants, residues, and adulterants across a wide array of sample types, where regulatory thresholds require sensitive and reliable measurement.

Environmental monitoring agencies and industrial customers use Waters’ separation and detection tools to track pollutants, process by-products, and compliance metrics in water, soil, and air samples.

Clinical and translational research centers apply Waters’ analytical technologies to biomarker discovery and validation, supporting personalized medicine initiatives that depend on accurate molecular characterization.

Current trading snapshot

As of a recent completed trading session in August 2026, Waters Corp is listed on the New York Stock Exchange under the ticker WAT, with shares changing hands in US dollars.

At the $411.88 opening price reported for the mid-August 2026 session, Waters’ equity valuation reflects both the company’s role in high-end analytical instrumentation and the premium multiples highlighted in recent valuation analysis.

Investors comparing Waters stock with broader life sciences peers can use the juxtaposition of the 8.7 times price-to-sales multiple against the 4.1 times industry average and the 5.3 times peer group average, alongside the Q3 2026 EPS guidance of $3.95 to $4.05 and full-year 2026 EPS guidance of $14.45 to $14.65, to judge whether the current share price continues to offer attractive risk-reward.

Facts and figures on Waters stock

Company: Waters Corp Inc.

ISIN: US9418481035

Ticker: WAT

Exchange: New York Stock Exchange

Price (as of August 17, 2026, 10:33 a.m. ET): $411.88 USD

Market cap: data based on recent valuation multiples and revenue context

Sector / Industry: Life sciences tools and services

Index membership: relevant US equity index memberships for large-cap analytical instrument providers